Integrated Filing — IndAS


General information about company

Scrip Code 541540
NSE Symbol SOLARA
MSEI Symbol NOTLISTED
ISIN INE624Z01016
Name of company Solara Active Pharma Sciences Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 15-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 07-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Active Pharmaceuticals Ingredient (API)
Start date and time of board meeting 15-May-2025   12:15:00
End date and time of board meeting 15-May-2025   14:10:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public No
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. No
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-05-15
Indicate Company website link for updated RPT policy of the Company https://solara.co.in/investor-relations/policies-and-guidelines/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Unaudited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2730100000 12837600000
Other income 59500000 91400000
Total income 2789600000 12929000000
2 Expenses
(a) Cost of materials consumed 1436700000 5816600000
(b) Purchases of stock-in-trade 50500000 57500000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -306300000 390000000
(d) Employee benefit expense 522800000 2116800000
(e) Finance costs 291200000 1148100000
(f) Depreciation, depletion and amortisation expense 243000000 992500000
(f) Other Expenses
1 Other expenses 600500000 2418300000
Total other expenses 600500000 2418300000
Total expenses 2838400000 12939800000
3 Total profit before exceptional items and tax -48800000 -10800000
4 Exceptional items 0 0
5 Total profit before tax -48800000 -10800000
6 Tax expense
7 Current tax 0 0
8 Deferred tax 0 0
9 Total tax expenses 0 0
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations -48800000 -10800000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period -48800000 -10800000
17 Other comprehensive income net of taxes -6400000 10600000
18 Total Comprehensive Income for the period -55200000 -200000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 402500000 402500000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 0
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations -1.65 -0.27
Diluted earnings (loss) per share from continuing operations -1.65 -0.27
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations -1.65 -0.27
Diluted earnings (loss) per share from continuing and discontinued operations -1.65 -0.27
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 7320800000
Capital work-in-progress 2800500000
Investment property 22800000
Goodwill 3649000000
Other intangible assets 298000000
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 17000000
Trade receivables, non-current
Loans, non-current 0
Other non-current financial assets 163200000
Total non-current financial assets 180200000
Deferred tax assets (net)
Other non-current assets 693700000
Total non-current assets 14965000000
2 Current assets
Inventories 3179000000
Current financial asset
Current investments 0
Trade receivables, current 3265700000
Cash and cash equivalents 38100000
Bank balance other than cash and cash equivalents 1600000
Loans, current 200000
Other current financial assets 123600000
Total current financial assets 3429200000
Current tax assets (net)
Other current assets 677800000
Total current assets 7286000000
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 22251000000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 402500000
Other equity 10559600000
Total equity attributable to owners of parent 10962100000
Non controlling interest
Total equity 10962100000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 1138600000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities 181900000
Total non-current financial liabilities 1320500000
Provisions, non-current 98500000
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities 489200000
Total non-current liabilities 1908200000
Current liabilities
Current financial liabilities
Borrowings, current 6622000000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 379900000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2046000000
Total Trade payable 2425900000
Other current financial liabilities 201400000
Total current financial liabilities 9249300000
Other current liabilities 109100000
Provisions, current 22300000
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 9380700000
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 11288900000
Total equity and liabilites 22251000000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Unaudited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Unaudited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement gains/(losses) of defined benefit plans -6400000 10600000
Total Amount of items that will not be reclassified to profit and loss -6400000 10600000
2 Income tax relating to items that will not be reclassified to profit or loss 0 0
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income -6400000 10600000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax -10800000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1148100000
Adjustments for decrease (increase) in inventories 418000000
Adjustments for decrease (increase) in trade receivables, current 197400000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -100300000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current -593300000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 104400000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 992500000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -14700000
Adjustments for dividend income 0
Adjustments for interest income 7600000
Adjustments for share-based payments 26800000
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow -10200000
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items -13300000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 2147800000
Net cash flows from (used in) operations 2137000000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 9000000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 2128000000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 9600000
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 3800000
Purchase of property, plant and equipment 399400000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 7500000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 10200000
Net cash flows from (used in) investing activities -368300000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 1590200000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 750000000
Repayments of borrowings 2963800000
Payments of lease liabilities 21300000
Dividends paid 0
Interest paid 1131000000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -28900000
Net cash flows from (used in) financing activities -1804800000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -45100000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -45100000
Cash and cash equivalents cash flow statement at beginning of period 83200000
Cash and cash equivalents cash flow statement at end of period 38100000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Delloitte Haskins & Sells LLP Yes 31-Jul-2027


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date



Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Mode of Fund Raising Rights Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 19-Jun-2024
Amount Raised 1574800000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CRISIL RATINGS LIMITED
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation NA
Comments of the Audit Committee after review No comments from the Audit Committee
Comments of the auditors, if any Not Applicable
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Repayment or Pre payment in full or part of certain outstandings Borrowings availed by the Company NIL 1186100000 0 1186100000 0 No of funds raised during the quarter is 0
2 General Corporate Purpose NIL 358700000 0 358700000 0 No of funds raised during the quarter is 0


Signatory Details

Name of signatory S Murali Krishna
Designation of person Company Secretary and Compliance Officer
Place Chennai
Date 15-May-2025




Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity /subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Solara Active Pharma Sciences Limited Aurore Life Sciences Private Limited Enterprises controlled, owned or significantly influenced by directors, key management personnel, promoter or person holding significant interest in the company Sale of goods or services 50000000 Nil 400000 32400000 2700000
2 Solara Active Pharma Sciences Limited Aurore Life Sciences Private Limited* Enterprises controlled, owned or significantly influenced by directors, key management personnel, promoter or person holding significant interest in the company Any other transaction Recovery of expenses 0 Nil 0 0 0
3 Solara Active Pharma Sciences Limited Aurore Pharmaceuticals Private Limited Enterprises controlled, owned or significantly influenced by directors, key management personnel, promoter or person holding significant interest in the company Sale of goods or services 50000000 Nil 0 81600000 0
4 Solara Active Pharma Sciences Limited Aurore Pharmaceuticals Private Limited Enterprises controlled, owned or significantly influenced by directors, key management personnel, promoter or person holding significant interest in the company Purchase of goods or services 0 Nil 0 0 0
5 Solara Active Pharma Sciences Limited Axxelent Pharma Sciences Private Limited Enterprises controlled, owned or significantly influenced by directors, key management personnel, promoter or person holding significant interest in the company Sale of goods or services 0 Nil 0 0 0
6 Solara Active Pharma Sciences Limited Axxelent Pharma Sciences Private Limited Enterprises controlled, owned or significantly influenced by directors, key management personnel, promoter or person holding significant interest in the company Purchase of goods or services 0 Nil 0 0 0
7 Solara Active Pharma Sciences Limited Batliboi Impex Limited Enterprises controlled, owned or significantly influenced by director Purchase of goods or services 0 Nil 0 0 0
8 Solara Active Pharma Sciences Limited Jitesh Devendra Director and Key Management Personnel Any other transaction Short term employee benefits 0 Nil 0 0 0
9 Solara Active Pharma Sciences Limited Karuna Business Solutions LLP Promoter group Any other transaction Recovery of expenses 0 Nil 0 0 0
10 Solara Active Pharma Sciences Limited Kausalya Santhanam Director Any other transaction Sitting fees paid to directors 500000 Nil 500000 0 0
11 Solara Active Pharma Sciences Limited Nirmal P Bhogilal Director Any other transaction Sitting fees paid to directors 0 Nil 0 0 0
12 Solara Active Pharma Sciences Limited R. Ramakrishnan Director Any other transaction Sitting fees paid to directors 600000 Nil 600000 0 0
13 Solara Active Pharma Sciences Limited S Hariharan Director and Key Management Personnel Any other transaction Short term employee benefits 0 Nil 0 0 0
14 Solara Active Pharma Sciences Limited Poorvank Purohit Director and Key Management Personnel Any other transaction Short term employee benefits 24800000 Nil 24800000 0 0
15 Solara Active Pharma Sciences Limited Sandeep Rao Director and Key Management Personnel Any other transaction Short term employee benefits 3500000 Nil 3500000 0 0
16 Solara Active Pharma Sciences Limited Arun Kumar Baskaran Key Management Personnel Any other transaction Short term employee benefits 2500000 Nil 2500000 0 0
17 Solara Active Pharma Sciences Limited Sarat Kumar Key Management Personnel Any other transaction Short term employee benefits 1000000 Nil 1000000 0 0
18 Solara Active Pharma Sciences Limited S Murali Krishna Key Management Personnel Any other transaction Short term employee benefits 3000000 Nil 3000000 0 0
19 Solara Active Pharma Sciences Limited One source speciality Pharma limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Sale of goods or services 1000000 Nil 1000000 40400000 700000
20 Solara Active Pharma Sciences Limited One source speciality Pharma limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Sale of goods or services 0 Nil 0 0 0
21 Solara Active Pharma Sciences Limited Steriscience Specialties Pvt Ltd Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Sale of goods or services 50000000 Nil -4600000 5600000 100000
22 Solara Active Pharma Sciences Limited Strides Pharma Science Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Any other transaction Other operating revenue 10000000 Nil 4400000 0 0
23 Solara Active Pharma Sciences Limited Strides Pharma Science Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Any other transaction Recovery of expenses 100000000 Nil 76500000 0 0
24 Solara Active Pharma Sciences Limited Strides Pharma Science Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Any other transaction Rent & Maintenance for leased property 8800000 Nil 8800000 0 0
25 Solara Active Pharma Sciences Limited Strides Pharma Science Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Sale of goods or services 1871200000 Nil 795400000 943000000 609400000
26 Solara Active Pharma Sciences Limited Strides Pharma Science Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Sale of fixed assets 0 Nil 0 0 0
27 Solara Active Pharma Sciences Limited Strides Pharma Science Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Sale of goods or services 0 Nil 0 0 0
28 Solara Active Pharma Sciences Limited Strides Pharma Science Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Any other transaction Security deposit given 0 Nil 0 7200000 7200000
29 Solara Active Pharma Sciences Limited Strides Pharma Science Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Purchase of goods or services 0 Nil 0 0 0
30 Solara Active Pharma Sciences Limited Strides Pharma Science Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Any other transaction Reimbursement of expenses 10000000 Nil 10200000 1500000 4800000
31 Solara Active Pharma Sciences Limited Tenshi Pharmaceuticals Private Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Any other transaction Reimbursement of expenses 369400000 Nil 20100000 8700000 8900000
32 Solara Active Pharma Sciences Limited Tenshi Pharmaceuticals Private Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Any other transaction Guarantee commission paid 900000 Nil 900000 0 0
33 Solara Active Pharma Sciences Limited Tenshi Pharmaceuticals Private Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Any other transaction Loan repaid 0 Nil 0 180000000 0
34 Solara Active Pharma Sciences Limited Tenshi Kaizen Private Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Sale of goods or services 37500000 Nil 900000 100000 0
35 Solara Active Pharma Sciences Limited Tenshi Kaizen Private Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Sale of goods or services 37500000 Nil 100000 1500000 1200000
36 Solara Active Pharma Sciences Limited Tenshi Pharmaceuticals Private Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Interest paid 2800000 Nil 2800000 0 0
37 Solara Active Pharma Sciences Limited Chayadeep Properties Private Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Interest paid 1900000 Nil 1900000 0 0
38 Solara Active Pharma Sciences Limited Chayadeep Properties Private Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Any other transaction Loan repaid 105000000 Nil 105000000 0 0
39 Solara Active Pharma Sciences Limited Chayadeep Properties Private Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Any other transaction Loan receipt 105000000 Nil 105000000 0 0
40 Solara Active Pharma Sciences Limited Aurore Pharmaceuticals Private Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Any other transaction Claims received 0 Nil 0 0 0
41 Solara Active Pharma Sciences Limited Aurore Life Sciences Private Limited Enterprises controlled, owned or significantly influenced by directors, promoter or person holding significant interest in the company Any other transaction Claims received 0 Nil 0 0 0
42 Solara Active Pharma Sciences Limited Vineeta Rai Director Any other transaction Sitting fees paid to directors 0 Nil 0 0 0
43 Solara Active Pharma Sciences Limited Mohan M Director and Key Management Personnel Any other transaction Short term employee benefits 10300000 Nil 10300000 0 0
44 Solara Active Pharma Sciences Limited Rajiv Vijay Nabar Director Any other transaction Sitting fees paid to directors 600000 Nil 600000 0 0
45 Solara Active Pharma Sciences Limited Rajendra Kumar Srivastava Director Any other transaction Sitting fees paid to directors 600000 Nil 600000 0 0
46 Solara Active Pharma Sciences Limited Manish Gupta Director Any other transaction Sitting fees paid to directors 300000 Nil 300000 0 0
Total value of transaction during the reporting period 1176500000





Format for Disclosing Outstanding Default on Loans and Debt Securities

Sr. No. Particulars Amount Remarks
1. Loans / revolving facilities like cash credit from banks / financial institutions
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
2. Unlisted debt securities i.e. NCDs and NCRPS
A Total amount outstanding as on date
B Of the total amount outstanding, amount of default as on date
3. Total financial indebtedness of the listed entity including short-term and long-term debt